Abstract
Background Brazil, the country most impacted by the coronavirus disease 2019 (COVID-19) on the southern hemisphere, uses mobility indices to monitor quarantines. In this study we quantified the associations between residential mobility index (RMI), air pollution, meteorology, and daily cases and deaths of COVID-19 in São Paulo, Brazil
Objectives To acquire time-series data to estimate the associations between daily residential mobility index (RMI), air pollution, and meteorology, and daily cases and deaths for COVID-19 in São Paulo, Brazil.
Methods We applied a semiparametric generalized additive model (GAM) to estimate: 1) the association between residential mobility index and cases and deaths due to COVID-19, accounting for ambient particulate matter (PM2.5), ozone (O3), relative humidity, temperature and delayed exposure between 3-21 days and 2) the association between exposure to for ambient particulate matter (PM2.5), ozone (O3), accounting for relative humidity, temperature and mobility.
Results We found an RMI of 45.28% results in 1,212 cases (95% CI: 1,189 to 1,235) and 44 deaths (95% CI: 40 to 47). Reducing mobility 5% would avoid 438 cases and 21 deaths. Also, we found that an increment of 10 μg·m-3 of PM2.5 risk of 1.140 (95% CI: 1.021 to 1.274) for cases and of 1.086 (95% CI: 1.008 to 1.170) for deaths, while O3 produces a relative risk of 1.075 (95% CI: 1.006 to 1.150) for cases and 1.063 (95% CI: 1.006 to 1.124) for deaths, respectively.
Discussion We compared our results with observations and literature review, finding well agreement. These results implicate that authorities and policymakers can use such mobility indices as tools to support social distance activities and assess their effectiveness in the coming weeks and months. Small increments of air pollution pose a risk of COVID-19 cases.
Conclusion Spatial distancing is a determinant factor to control cases and deaths for COVID-19. Small increments of air pollution result in a high number of COVID-19 cases and deaths. PM2.5 has higher relative risks for COVID-19 than O3.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by FAPESP (Grants No. 2015/03804-9, 2016/18438-0 and 2016/10557-0) and "Coordenaçã o de Aperfeiçoamento de Pessoal de Nivel Superior - Brasil" (CAPES) Finance Code 001;
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our manuscript is based on public data, hence, it was not necessary to obtain approvals from ethics committee
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All the data used in this manuscript and the scripts to reproduce the results and figures are available at https://gitlab.com/ibarraespinosa/covid191
